Beyond the trial: how will SELUTION DeNovo redefine our PCI practice?

Sponsored by Cordis

Anchorperson: T. Johnson

Spokespersons: O. Al Shammeri, I. Al Rashdan, H. Kassem

Summary

This session looks beyond trial data to examine how the SELUTION DeNovo study may reshape PCI practice in real-world settings.

The discussion reviews key clinical results from this large-scale DeNovo PCI trial and explains the technology behind the SELUTION SLR drug-eluting balloon, including its slow-flow drug delivery and what sets it apart from other DEBs.

Through expert case sharing, the session illustrates how DEBs can be integrated into daily practice, even in complex and high-risk lesions, supporting a potential shift toward a DEB-first strategy that prioritises vessel preservation, reduces implant burden, and maintains flexibility for future interventions.

Learning Objectives

To review the SELUTION DeNovo study results and understand their potential impact on clinical practice
To understand the technology behind the SELUTION slow flow after DEB and what differentiates it as a unique balloon
To learn how to integrate DEBs into clinical practice through expert case sharing